TLDR
-
Leap surges 58% as Winklevoss leads $58.9M PIPE, merging biotech and crypto.
-
Leap rockets 58% after $58.9M PIPE; Winklevoss backs biotech-crypto strategy.
-
Winklevoss Capital fuels Leapās 58% rally with $58.9M biotech-crypto PIPE.
-
Leap rises 58% on $58.9M Winklevoss-led deal blending biotech and blockchain.
-
$58.9M PIPE ignites Leapās biotech-crypto pivot; Winklevoss takes the helm.
Leap Therapeutics surged nearly 58% during early trading, reaching $0.8429 after announcing a $58.9 million PIPE financing deal.
The transaction, led by Winklevoss Capital, propelled buying interest as the stock later stabilized between $0.81 and $0.84. The company plans to use the new capital for both clinical advancements and digital asset strategy.
The PIPE offering includes over 95 million common shares or pre-funded warrants and more than 71 million common stock warrants. Each unit was priced at $0.61439, with warrants exercisable at $0.5335 per share. This pricing satisfies Nasdaqās āMinimum Priceā rule, aligning with regulatory compliance.
This new agreement marks a pivotal shift in Leapās financial strategy, integrating crypto assets with its biotech development goals. Winklevoss Capital will not only supply funds but also offer guidance in implementing the digital treasury strategy. The financing aims to create long-term shareholder value while strengthening Leapās clinical and financial footing.
Winklevoss Capital Brings Strategic Control and Board Influence
Leap Therapeutics will expand its board of directors to 12 members, enhancing governance flexibility. Winklevoss Capital gains the right to nominate two directors, one of whom will serve as chairperson. This inclusion reflects a deeper strategic partnership beyond financial support.
Winklevoss Capitalās involvement signals a move toward active portfolio management and governance at Leap. Their participation aims to bridge financial innovation with the companyās clinical ambitions. The collaboration combines biotech expertise and digital asset exposure, positioning Leap for unconventional growth pathways.
Legal representation for the transaction includes Morgan, Lewis & Bockius LLP for Leap and Cooley LLP for Winklevoss Capital. The securities will be offered under Regulation D and Section 4(a)(2) exemptions from the Securities Act of 1933. A resale registration statement is expected to follow for transparency and compliance.
Funding Supports Key Drug Programs Including ESMO-Featured Therapy
Leap will channel part of the funds into its therapeutic pipeline, particularly FL-501 and sirexatamab, two promising cancer drug candidates. Sirexatamab recently completed a Phase 2 trial in colorectal cancer and will be presented at the ESMO Congress 2025 in Berlin. This milestone underscores Leapās commitment to clinical progress alongside financial innovation.
The trial’s inclusion in a Mini Oral Session highlights the clinical relevance of Leapās drug development efforts. The company aims to maintain this momentum through targeted capital allocation from the PIPE deal. Development updates are expected as the company advances toward potential late-stage trials.
Parcrest serves as the placement agent for the offering, which is expected to close on or around October 8, 2025. Leap plans to provide further updates on its crypto treasury rollout shortly. The dual-track strategy combining biotech R&D and digital asset investment sets a bold new direction.
šØ Our MAY Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for May, highlighting companies with strong momentum that rank highly on our KO Score algorithm. Weāre also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
